This trial is conducted in Europe. The aim of this dose-escalating trial is to assess safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of single and repeated doses of NNC141-0100 in subjects with Rheumatoid Arthritis.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01370902?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
